

Submit medical drug prior authorization requests online

As part of our efforts to make the prior authorization (PA) process more efficient, we're encouraging prescribers register and use our Web-based system when prescribing medical drugs for commercial members. This new application gives providers the ability to submit forms electronically and the ability to lookup the status of their medical drug PA request.

In-state Providers

In order to be able to submit your prior authorization requests electronically, you will need to:

- Become a registered Availity user by clicking the following hyperlink, avility.com/bcbsm, and following the steps.

To request a drug prior authorization, please go to bcbsm.com and follow these easy steps:

Log into the Availity

- Navigate to avility.com, and enter your provided username and password
- Click the Payer Spaces drop down and select BCBSM BCN icon
- Scroll down the page and select the appropriate Novologix link for your member

Complete the Prior Authorization Request

- To login to Novologix, enter your User ID and Password
- Click the Authorizations drop down and select Create Authorization
- Enter in the members specific details and select the correct member on contract
- Complete the required fields and select the correct drug product in the Authorization Lines section
- Click Submit and complete the question to request prior authorization

Out-of-State Providers

In order to be able to submit your prior authorization requests electronically, you will need to:

- Access the Electronic Provider Access (EPA) via local Blues Plan
 - Download the Registration form for electronic access from the Medical Prior Authorization Review link
- AND**
- Submit the Registration form with a completed Medication Authorization Request Form (MARF) via fax or mail
 - For additional information or instructions, please refer to the e-Learning Training Modules in the Provider Secure Services page OR contact the Help Desk at 877-258-3932

Disclaimer: Access is only available to registered users. A valid individual NPI is required for registration.

Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form
Vyvgart™ (efgartigimod alfa-fcab)
HCP CODE: J9332



This form is to be used by participating physicians to obtain coverage for Vyvgart. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	Name
ID Number	Specialty
D.O.B. <input type="checkbox"/> Male <input type="checkbox"/> Female	Address
Diagnosis	City /State/Zip
Drug Name	Phone/Fax: P: () - F: () -
Dose and Quantity	NPI
Directions	Contact Person
Date of Service(s)	Contact Person Phone / Ext.

STEP 1: DISEASE STATE INFORMATION

1. Is this request for: Initiation Continuation **Date patient started therapy:** _____
2. Site of administration? Provider office/Home infusion Other: _____
 Hospital outpatient facility (go to #3) Reason for Hospital Outpatient administration: _____
3. Please specify location of administration if hospital outpatient infusion: _____
4. Please provide the NPI number for the place of administration: _____

5. Initiation AND Continuation of therapy:

- a. Please check the patient's diagnosis: Generalized myasthenia gravis with anti-acetylcholine receptor (AChR) positivity (gMG)
 Other: _____
- b. How was the patient identified to be anti-acetylcholine receptor (AChR) antibody-positive? (**Please attach any tests confirming diagnosis**)
 Anti-AChR antibody test Edrophonium test Clinical response to oral cholinesterase inhibitors (ex. pyridostigmine)
 Repetitive nerve stimulation (RNS) Single-fiber electromyography (SFEMG) Other: _____
- c. Does the patient have a history of thymectomy within 3 months, current thymoma, or other neoplasms of the thymus?
 yes, Date: _____ no
- d. Which medication did the patient trial and fail for at least 12 weeks?
 Methotrexate, Date started: _____ Date ended: _____
 Azathioprine, Date started: _____ Date ended: _____
 Cyclosporine, Date started: _____ Date ended: _____
 Cyclophosphamide, Date started: _____ Date ended: _____
 Mycophenolate mofetil, Date started: _____ Date ended: _____
 Tacrolimus, Date started: _____ Date ended: _____
 Other: _____, Date started: _____ Date ended: _____
- e. Is the patient currently receiving and will continue to receive a standard of care regimen for their diagnosis with Vyvgart?
 Yes No Comment: _____
- f. Will the patient be receiving Vyvgart concurrently with other biologic therapies for myasthenia gravis or immunoglobulin therapy?
 yes no Comment: _____

6. Continuation request: Vyvgart start date _____

- a. Has the patient's condition improved while on therapy with Vyvgart? Yes No Comment _____

Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date
Step 2: Checklist	<input type="checkbox"/> Form Completely Filled Out <input type="checkbox"/> Attached Chart Notes	<input type="checkbox"/> Concurrent Medical Problems <input type="checkbox"/> Prior Therapies
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.